January 11, 2006
The Teikoku Group announced today it has licensed the rights to develop and market LAB Pharma’s fast-acting analgesic Fentanyl Taifun in Japan. Under the terms of the agreement, LAB will receive a signing fee, development milestones payments and R&D reimbursements for development activities conducted by Lab in support of the development in Japan. In addition, Teikoku will pay LAB royalties on sales and manufacturing revenues for supplying the finished product.
Click here to download
Visit Teikoku Seiyaku's
|Copyright © 2010 Teikoku Pharma USA, Inc. All Rights Reserved.|
|Designed & Developed by CLI Interactive & HBG Health|